Actively Recruiting
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis
Led by Hua Jiang · Updated on 2026-01-02
30
Participants Needed
1
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colon cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colon cancer patients with liver metastasis.
CONDITIONS
Official Title
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed advanced colon cancer with liver metastasis by histology or cytology
- Signed written informed consent
- No prior anti-tumor treatment
- At least one measurable target lesion per RECIST v1.1
- Age between 18 and 75 years, any gender
- ECOG performance status of 0 or 1
- Expected survival of at least 3 months
- Adequate organ and bone marrow function within 7 days before enrollment, including: blood counts, liver function, renal function, and coagulation within specified limits
- Negative pregnancy test for women of reproductive age within 3 days before first treatment
- Women of childbearing potential agree to use contraception or abstain from heterosexual intercourse
- Men agree to use condoms or abstain from heterosexual intercourse and agree not to donate sperm
You will not qualify if you...
- History of other malignancies within 5 years, except certain cured skin, cervical, or thyroid cancers
- Planned elective surgery during the trial
- Inability to take oral medications or significant gastrointestinal absorption issues
- Pregnancy or breastfeeding
- Central nervous system or meningeal metastasis
- Uncontrolled bone metastasis or risk of fracture requiring surgery or radiation
- Active infections needing systemic treatment
- History of immunodeficiency including HIV positivity
- Known active autoimmune diseases
- Uncontrolled active hepatitis B or hepatitis C infection
- Severe cardiovascular or cerebrovascular disease history
- Serious bleeding events or high bleeding risk factors in past 6 months
- Diabetes not stably controlled by medication
- Mental or communication disorders preventing study participation
- Participation in another clinical trial
- MSI-H/dMMR status without immunotherapy or specific genetic exclusions
- Other serious systemic diseases or conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second People's Hospital of Changzhou
Changzhou, China
Actively Recruiting
Research Team
H
Hua Jiang MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here